home / stock / crvs / crvs quote
Last: | $1.45 |
---|---|
Change Percent: | -2.03% |
Open: | $1.56 |
Close: | $1.48 |
High: | $1.6193 |
Low: | $1.44 |
Volume: | 114,196 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.45 | $1.56 | $1.48 | $1.6193 | $1.44 | 114,196 | 04-26-2024 |
$1.48 | $1.47 | $1.48 | $1.52 | $1.4101 | 66,282 | 04-25-2024 |
$1.51 | $1.6 | $1.51 | $1.6 | $1.49 | 90,571 | 04-24-2024 |
$1.53 | $1.43 | $1.53 | $1.57 | $1.43 | 137,350 | 04-23-2024 |
$1.44 | $1.39 | $1.44 | $1.5 | $1.39 | 130,642 | 04-22-2024 |
$1.4 | $1.4 | $1.4 | $1.44 | $1.36 | 58,804 | 04-19-2024 |
$1.41 | $1.38 | $1.41 | $1.45 | $1.3 | 140,418 | 04-18-2024 |
$1.36 | $1.5 | $1.36 | $1.5099 | $1.36 | 112,527 | 04-17-2024 |
$1.47 | $1.44 | $1.47 | $1.51 | $1.36 | 91,660 | 04-16-2024 |
$1.47 | $1.53 | $1.47 | $1.5364 | $1.41 | 69,358 | 04-15-2024 |
$1.53 | $1.6 | $1.53 | $1.6205 | $1.5 | 155,480 | 04-12-2024 |
$1.56 | $1.61 | $1.56 | $1.61 | $1.5201 | 122,961 | 04-11-2024 |
$1.51 | $1.67 | $1.51 | $1.67 | $1.46 | 231,063 | 04-10-2024 |
$1.63 | $1.71 | $1.63 | $1.78 | $1.6 | 196,127 | 04-09-2024 |
$1.71 | $1.75 | $1.71 | $1.7899 | $1.68 | 120,413 | 04-08-2024 |
$1.75 | $1.68 | $1.75 | $1.78 | $1.63 | 190,703 | 04-05-2024 |
$1.69 | $1.77 | $1.69 | $1.85 | $1.685 | 211,179 | 04-04-2024 |
$1.75 | $1.83 | $1.75 | $1.86 | $1.73 | 490,276 | 04-03-2024 |
$1.86 | $1.83 | $1.86 | $1.9378 | $1.78 | 121,773 | 04-02-2024 |
$1.86 | $1.78 | $1.86 | $1.89 | $1.74 | 117,250 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Corvus Pharmaceuticals Inc. Company Name:
CRVS Stock Symbol:
NASDAQ Market:
Corvus Pharmaceuticals Inc. Website:
Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus anticipates releasing initial clinical data from trial before year-end 2024 BURLINGAME, Calif., April 09, 2024 (GLOBE NEWSWIRE...
Soquelitinib advancing towards initial enrollment for registrational Phase 3 clinical trial for PTCL and randomized Phase 1 clinical trial for atopic dermatitis Orphan drug designation and new interim data from Phase 1/1b clinical trial further demonstrate soquelitinib’s potentia...
BURLINGAME, Calif., March 13, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, ...